ArticleFrontiers in medicine2026
Application of a MRI model based on tumor microenvironment habitat and peritumoral features in preoperative differentiation of rectal cancer T1-2/T3: a multicenter study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To develop a MRI model integrating tumor microenvironment (TME)-driven habitat analysis, peritumoral radiomics, and clinical risk factors for improving preoperative differentiation of T1-2 and T3 stages in rectal cancer. Methods: This retrospective multicenter study included 313 patients (training cohort: 183; external test cohort: 130). MRI-derived intratumoral radiomic features were clustered into three TME habitats using K-means, while peritumoral features (1 mm, 2 mm, 3 mm extensions) were extracted. Feature selection and model construction were performed using LASSO regression and cross-validation, with all steps strictly confined to the training cohort. Four models were evaluated: peritumoral (PERI2mm optimal), habitat, clinical, and a nomogram combining radiomic features (habitat and PERI2mm) with clinical predictors. Performance was assessed using ROC curves, calibration metrics (intercept, slope, Brier score), and decision curve analysis (DCA). Results: The nomogram achieved the highest AUC of 0.907 (training) and 0.881 (test), outperforming standalone models in the test cohort (PERI2mm: AUC = 0.721; habitat: AUC = 0.741; clinical: AUC = 0.723). The nomogram also demonstrated superior balanced accuracy (0.827), PR-AUC (0.948), and F1 score (0.851) in the test cohort. Key clinical predictors included age, elevated CEA, tumor length, circumferential growth and mrT stage. Calibration analysis confirmed excellent agreement between predicted and pathological staging, with the nomogram showing the lowest Brier scores (0.1214 training, 0.1253 test) and intercepts near zero, indicating no significant systematic bias. DCA demonstrated superior clinical net benefit across risk thresholds. Conclusion: The TME-integrated nomogram significantly enhances preoperative T1-2/T3 staging accuracy in rectal cancer by leveraging habitat heterogeneity, peritumoral radiomics, and clinical biomarkers, with robust calibration and generalization. This tool may refine therapeutic strategies, reduce overtreatment, and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.